GlassScriptPhysician profile
Erin Casey
NPI 1386254753
$3,001.53
in general payments reported to CMS, 2019-2025
22 companies · $1,358 in 2025
The $1,358 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $42.05 · 2024: $1,601 · 2025: $1,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,001.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $712.36 | 2024-2025 | Breztri, Airsupra, Bevespi Aerosphere |
| Novo Nordisk INC | $402.46 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $391.18 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $282.01 | 2024-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $267.15 | 2024-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $177.49 | 2024-2025 | |
| Mylan Specialty L.P. | $124.30 | 2023-2024 | Yupelri |
| Lundbeck LLC | $96.16 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $84.63 | 2024-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $73.76 | 2024 | Voquezna |
| Exact Sciences Corporation | $63.60 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.48 | 2025 | Caplyta |
| Dexcom, INC. | $50.17 | 2024 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $38.40 | 2025 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $32.73 | 2024 | Gardasil, Vaxelis, Gardasil 9 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $30.93 | 2025 | Yupelri |
| Amgen INC. | $27.68 | 2025 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $22.34 | 2025 | |
| Astellas Pharma US INC | $20.52 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $18.80 | 2025 | Bexsero |
| Idorsia Pharmaceuticals US INC | $15.94 | 2024 | Quviviq |
| Organon LLC | $12.44 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Casey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.